Ahead of World Diabetes Day
Patient Survey released identify severe knowledge gaps with 74% of patients don’t believe that type 2 diabetes is associated with increased cardiovascular diseases risks
Ahead of World Diabetes Day, the Emirates Diabetes Society released findings of survey targeting type 2 diabetes patients in order to understand their perceptions, motivations and current disease management practices
74% of patients surveyed don’t believe that type 2 diabetes is associated with increased cardiovascular risk
‘Close to Your Heart’ campaign, a disease awareness campaign, has been developed by the support of Boehringer Ingelheim, in an effort to bridge the knowledge gap on the link between type 2 diabetes and cardiovascular diseases (CVDs)
United Arab Emirates, Dubai – 6 November 2018: The Emirates Diabetes Society has released findings of a Type 2 Diabetes Patient survey conducted this year by Ipsos, a global market research and a consulting firm, by the support of Boehringer Ingelheim, one of the world’s leading pharmaceutical companies. The survey findings were released along with a launch of a disease awareness Campaign ‘Close To Your Heart’, in an effort to understand the current patient profiles and lifestyles along with their insights and knowledge around the link between Type 2 Diabetes and Cardiovascular Diseases in the United Arab Emirates (UAE).
It corresponds to a time marked by a continued rise in type 2 diabetes across the region, putting people at an increasing risk of developing CVDs. There were as many as 1.185.500 cases of diabetes in the UAE in 2017.
More than 52% of patients with type 2 diabetes die of cardiovascular causes. Therefore, the epidemic of type 2 diabetes will be followed by an epidemic of diabetes-related CVDs. CVDs are also the number one cause of death globally, where more people die annually from CVDs than from any other cause.
The survey with input from among 604 in UAE has demonstrated a clear knowledge gap. The majority of respondents to the survey were males in 30- 40 year old age bracket and have visited a physician in the past 1-3 months. The survey unearthed considerably low awareness of type 2 diabetes and knowledge of the risk factors and after effects. The study also identified incorrect perceptions surrounding the disease, associated conditions and their management. Key findings include:
Half of those surveyed are unaware of high CV Risk- Half the total respondents are reported to be fully aware of the high CV risk associated with type 2 diabetes, despite more than half (57%) having discussed their condition with the treating physician to lower current risk. At the same time only 50% of patients believe they are at high risk of CV events, while 45% don’t associate heart disease to the condition.
Diabetes and Mortality- Only 20% agree that CVD is the number one cause of death for type 2 diabetes patients. Patients do not fully understand the seriousness of CV risk associated with diabetes. 55% do not believe it causes death. When it comes to perceived seriousness of diabetes, patients do not see it as a serious disease. From Cardiovascular diseases Stroke is seen as the serious disease followed by heart attacks and hypertension. Type 2 diabetes is also seen as the least serious disease, when looking at CVDs like stroke, heart attack and heart disease; patients consider them as significantly more serious.
Knowledge gap despite public awareness campaigns- Less than a third of the total respondents believe that they’re knowledgeable about type 2 diabetes. CVDs are yet to be identified as a health issue associated with diabetes. Patients perceive obesity to be more serious than type 2 diabetes confirms that increasing public awareness about a specific disease alters their perception.
Role of doctors- 34% of the respondents did not discuss cardiovascular diseases association with physicians. Most patients believe that type 2 diabetes is marked by high levels of blood sugar, followed by lack of insulin. The knowledge gap indicates the need for doctors to not just treat diabetes but also educate their patients on CV risk. Language used should reflect the seriousness of CV risk associated with type 2 diabetes to ensure that patients acknowledge and relate this risk to themselves
Understanding of Diabetes and Associated Diseases- Majority of patients suffer from associated symptoms like obesity and hypertension. Most patients believe that Type 2 diabetes is high levels of blood sugar, followed by lack of Insulin.
Dr. Abdulrazzaq Al Madani, President of the Emirates Diabetes Society said, “Type 2 diabetes is a serious epidemic, not only in the UAE, but around the world. Despite numerous efforts, awareness levels remain low, and there is a considerable gap when it comes to type 2 diabetes awareness and associated CV risk. The risks vary amongst individuals, therefore, it is crucial to leverage the physician patient relationship. Patients with type 2 diabetes are at an increased risk of developing heart disease and stroke.”
“When patients have both hypertension and diabetes, which is a common combination, the risk for CVDs doubles. It is important to assess one’s risk profile through regular checkups and have open conversations with their doctors. Given the importance and relationship between CVD and diabetes, there are new classes for type 2 diabetes treatment that showed significant improvement in cardiovascular death in their cardiovascular outcome trials, these classes are now more preferable for treatment than older classes for type 2 diabetes patients with established cardiovascular disease. Addressing the issue on a national level is key to control the widespread of diabetes in the UAE. It can be brought under control through the joint efforts and close collaboration of all the entities across the healthcare continuum,” added Dr. Al Madani.
In addition, Mazen Bachir, General Manager – Gulf at Boehringer Ingelheim said, “A key survey finding suggests that in the UAE, although type 2 diabetes see that stroke and heart attacks are very serious, they rarely relate them to being a consequence of diabetes. We believe that medical practitioners need to be encouraged to not just treat or manage diabetes, but also educate patients on CV risks. The launch of the ‘Close to Your Heart’ campaign comes at an important time as part of our efforts to bridge the gap between type 2 diabetes and associated CV risks. Managing type 2 diabetes right at the outset can help deliver better patient outcomes. Despite advances in care, CVDs are still the number one cause of death among people with type 2 diabetes.”
Bachir also noted, “Boehringer Ingelheim has a robust legacy in providing comprehensive care and management protocols for people with type 2 diabetes. We continue to invest in R&D excellence through research and collaboration, a broad and growing product portfolio and a continued determination to provide convenient solutions, to ultimately enhance the quality of life for all those affected by diabetes.”
The relationship between diabetes and CV disease is complex; diabetes is a risk factor for CVDs and conditions such as high blood pressure, stroke and heart attacks that are more common in people with diabetes. As part of the survey release, The Emirates Diabetes Society by the support of Boehringer Ingelheim launched ‘Close To Your Heart’ awareness campaign with a focus on type 2 diabetes patients sharing their experience around the disease, and calling for the family to come together to prevent cardiovascular conditions from aggravating. It will include a knowledge library that curates information from both the medical community and patient stories. The permanent digital library will be live on a dedicated website, available at http://closetoyourheart.me, with supporting content including a digital 360 campaign that features an awareness video, infographics and several media activities.
About Emirate Diabetes Society
The Emirates Diabetes Society (EDS) is a non-profit medical society which was established in 1996. EDS represents a cross section of specialist physicians and healthcare providers who are actively involved in the management of diabetes and endocrinology.
The Emirates Diabetes Society is the primary medical society in the United Arab Emirates and its primary objective isto increase public awareness and encourage health improvement, promote the exchange of high-quality information about diabetes, and provide education for people with diabetes and their healthcare providers. The society conducts a number of educational programs, which includes scientific as well as educational programs targeted towards Diabetes Educators.
About Boehringer Ingelheim
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on http://www.boehringer-ingelheim.com
or in our annual report: http://annualreport.boehringer-ingelheim.com
For further information, kindly contact:
Associate Director | Corporate and Healthcare practice lead
FleishmanHillard | United Arab Emirates
Head of External Communications – META
Boehringer Ingelheim | Middle East, Turkey and Africa